VERIGRAFT reports continued progress during the first quarter of 2026, with focus on regulatory interactions, operational readiness, and preparation for the company’s upcoming pivotal Phase II/III clinical trial (TECVI-2).
During the quarter, the CTA application progressed through validation and into the evaluation phase within the EU clinical trial framework. Requests for Information from regulatory authorities were addressed, and updated documentation was submitted.
Operational preparations also advanced during the quarter, including signing of contracts for manufacturing, data management, and CRO services supporting the clinical trial program.
In parallel, VERIGRAFT continued development activities across its P-TEA platform, externally funded projects, and patent portfolio.
VERIGRAFT will continue to provide updates in accordance with regulatory processes and ongoing development activities.